RYAN MACKINNON VASAPOLI AND BERZOK, LLP for GENENTECH
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Monitor Drug Safety and pedigree legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW BERZOK | — |
| NICK KOLOVOS | — |
| JEFF MACKINNON | — |
| JEFFERY C MORTIER New | — |
| THOMAS RYAN | — |
| JOSEPH V VASAPOLI | — |
Health Issues HCR
Implementation of H.R. 1; Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus. Issues relating to comparative effectiveness and CMS coverage of FDA approved therapies. Issues related to the PPS rule involving stroke guidelines. Implementation of the follow-on biologics provisions in P.L. 111-148- "Patient Protection and Affordable Care Act".
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW BERZOK | — |
| NICK KOLOVOS | — |
| JEFF MACKINNON | — |
| JEFFERY C MORTIER New | — |
| THOMAS RYAN | — |
| JOSEPH V VASAPOLI | — |
Medicare/Medicaid MMM
Implementation of H.R. 1; Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus. Issues relating to comparative effectiveness and CMS coverage of FDA approved therapies. Issues related to the PPS rule involving stroke guidelines. Proposals to reduce Medicare payment for Part B biologics.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW BERZOK | — |
| NICK KOLOVOS | — |
| JEFF MACKINNON | — |
| JEFFERY C MORTIER New | — |
| THOMAS RYAN | — |
| JOSEPH V VASAPOLI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.